The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 6, Issue 2, 2009, Pages 104-111

  Shaker, Saher B ^a   Dirksen, Asger ^a   Ulrik, Charlotte S ^b   Hestad, Marianne ^a   Stavngaard, Trine ^a   Laursen, Lars C ^a   Maltbaek, Niels ^a   Clementsen, Paul ^a   Skjaerbaek, Nanna ^c   Nielsen, Lars ^a   Stoel, Berend ^d   Skovgaard, Lene T ^e   Tonnesen, Philip ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c ASTRAZENECA   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

COPD; Inflammation; Lung density; Quantitative CT; Smoking

Indexed keywords

BUDESONIDE; PLACEBO; PREDNISOLONE; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SPIROMETRY; TOTAL LUNG CAPACITY; INHALATIONAL DRUG ADMINISTRATION; LUNG EMPHYSEMA; LUNG VOLUME; MIDDLE AGED; RADIOGRAPHY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; BUDESONIDE; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; LUNG VOLUME MEASUREMENTS; MALE; MIDDLE AGED; PULMONARY EMPHYSEMA; SMOKING; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 67650721221     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550902772593     Document Type: Article

References (40)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932-946.
2. Saetta M, KimWD, Izquierdo JL, Ghezzo H, CosioMG. Extent of centrilobular and panacinar emphysema in smokers' lungs: pathological and mechanical implications. Eur Respir J 1994; 7(4):664-671.
3. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320(7245):1297-1303.
4. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340(25):1948-1953.
5. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343(26):1902-1909.
6. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Longtermeffect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353(9167):1819-1823.
7. Confalonieri M, Mainardi E, Della PR, Bernorio S, Gandola L, Beghe B, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53(7):583-585.
8. Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK. Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 2002; 57(9):799-803.
9. Llewellyn-Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153(2):616-621.
10. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155(2):542-548.
11. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351(9105):773-780.
12. Spencer S, Calverley PM, Sherwood BP, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(1):122-128.
13. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356):449-456.
14. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6):912-919. (Pubitemid 37540641)
15. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(1):74-81. (Pubitemid 36150304)
16. Thurlbeck WM. Chronic Airflow Obstruction in Lung Disease. 1st ed. W. B. Saunders Company; 1976.
17. Flenley DC. Diagnosis and follow-up of emphysema. Eur Respir J Suppl 1990; 9:5s-8s.
18. Gould GA, MacNeeW, McLean A,Warren PM, Redpath A, Best JJ, et al. CT measurements of lung density in life can quantitate distal airspace enlargement-an essential defining feature of human emphysema. Am Rev Respir Dis 1988; 137(2):380-392.
19. Muller NL, Staples CA, Miller RR, Abboud RT. "Density mask". An objective method to quantitate emphysema using computed tomography. Chest 1988; 94(4):782-787.
20. Gevenois PA, De Maertelaer V, De Vuyst P, Zanen J, Yernault JC. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1995; 152(2):653-657.
21. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160(5 Pt 1):1468-1472.
22. Soejima K, Yamaguchi K, Kohda E, Takeshita K, Ito Y, Mastubara H, et al. Longitudinal follow-up study of smoking-induced lung density changes by high-resolution computed tomography. Am J Respir Crit Care Med 2000; 161(4 Pt 1):1264-1273.
23. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:5-40.
24. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity). ReportWorking Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:41-52.
25. Stoel BC, Stolk J. Optimization and standardization of lung densitometry in the assessment of pulmonary emphysema. Invest Radiol 2004; 39(11):681-688.
26. Shaker SB, Dirksen A, Laursen LC, Skovgaard LT, Holstein- Rathlou NH. Volume adjustment of lung density by computed tomography scans in patients with emphysema. Acta Radiol 2004; 45(4):417-423.
27. Stolk J, Dirksen A, van der Lugt AA, Hutsebaut J, Mathieu J, de Ree J, et al. Repeatability of lung density measurements with low-dose computed tomography in subjects with alpha-1- antitrypsin deficiency-associated emphysema. Invest Radiol 2001; 36(11):648-651.
28. Fischer BM, Mortensen J, Dirksen A, Eigtved A, Hojgaard L. Positron emission tomography of incidentally detected small pulmonary nodules. Nucl Med Commun 2004; 25(1):3-9.
29. Wagena EJ, van der Meer RM, Ostelo RJ, Jacobs JE, van Schayck CP. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 2004; 98(9):805-815.
30. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53(2):129-136.
31. Saetta M, Turato G, Baraldo S, Zanin A, Braccioni F, Mapp CE, et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 2000; 161(3 Pt 1):1016-1021.
32. Hogg JC, Chu F, Utokaparch S,Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(26):2645-2653.
33. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999; 93(3):161-166.
34. van der Valk J, Monninkhof E, van der PJ, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166(10):1358-1363.
35. Park KJ, Bergin CJ, Clausen JL. Quantitation of emphysema with three-dimensional CT densitometry: comparison with twodimensional analysis, visual emphysema scores, and pulmonary function test results. Radiology 1999; 211(2):541-547.
36. Dirksen A, Friis M, Olesen KP, Skovgaard LT, Sorensen K. Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT. Acta Radiol 1997; 38:826-832.
37. Willemse BWM, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23:464-476.
38. Gurney JW, Jones KK, Robbins RA, Gossman GL, Nelson KJ, Daughton D, et al. Regional distribution of emphysema: correlation of high-resolution CT with pulmonary function tests in unselected smokers. Radiology 1992; 183(2):457-463.
39. Kemerink GJ, Kruize HH, Lamers RJ, van Engelshoven JM. Density resolution in quantitative computed tomography of foam and lung. Med Phys 1996; 23(10):1697-1708.
40. Shaker SB, Dirksen A, Laursen LC, Maltbaek N, Christensen L, Sander U, et al. Short-term reproducibility of computed tomography-based lung density measurements in alpha-1 antitrypsin deficiency and smokers with emphysema. Acta Radiol 2004; 45(4):424-430.